Recent developments in urologic oncology: Positron emission tomography molecular imaging

Current Opinion in Oncology

Volumn 20, Issue 3, 2008, Pages 321-326

  Bouchelouche, Kirsten ^a   Oehr, Peter ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Bladder cancer; Positron emission tomography; Prostate cancer; Renal cancer; Testicular cancer

Indexed keywords

1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID ANTIBODY F 18; ACETIC ACID C 11; ANTIANDROGEN; CARBON 11; CARBOXYLIC ACID DERIVATIVE; CHIMERIC ANTIBODY G250 I 124; CHOLINE C 11; CHOLINE F 18; FLUORINE 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BLADDER CANCER; BONE METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MOLECULAR IMAGING; ORCHIECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; TESTIS CANCER; TRANSRECTAL ULTRASONOGRAPHY;

CARBON RADIOISOTOPES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 41949140966     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f8b02b     Document Type: Review

References (32)

1. Powles T, Murray I, Brock C, et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007; 51:1511-1520.
2. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006; 36:51-72.
3. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008; 179:34-45.
4. Oehr P, Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol 2007; 19:259-264.
5. Scher B, Seitz M, Albinger W, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:45-53.
6. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007; 244:797-806.
7. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:253-263.
8. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006; 47:262-269.
9. 11C-choline PET and TRUS in the preoperative staging in prostate cancer and demonstrates their limitations in estimates for the extension of disease.
10. 18F-FCH PET with delayed images is useful for detection of bone metastases in prostate cancer patients, however, the authors recommend that caution should be taken in patients who are under hormone therapy.
11. Cimitan M, Bortolus R, Morassut S, et al. [(18)F]Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33:1387-1398.
12. Ciernik IF, Brown DW, Schmid D, et al. 3D-Segmentation of the (18)F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat 2007; 6:23-30.
13. Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008; 35:9-17. This study indicates best that in patients with very low PSA levels and no evidence of active disease FCH PET/CT may be an aid to judge negative for local remission, and may be a diagnostic tool for the detection of recurrent prostate cancer in patients with even slightly elevated but increasing PSA.
14. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100:786-793.
15. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52:423-429.
16. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:18-23. The study gives good information about sensitivity and specificity in the relationship between the detection rate of 11C choline PET/CT and the serum PSA level.
17. Scher B, Seitz M. PET/CT imaging of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:45-53.
18. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 2006; 8:43-48.
19. Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 2007; 99:1415-1420.
20. Albrecht S, Buchegger F, Soloviev D, et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34:185-196.
21. Morris MJ, Scher HI. (11)C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:181-184.
22. Nanni C, Castellucci P, Farsad M, et al. 11C/18F-choline PET or 11C/ 18F-acetate PET in prostate cancer: may a choice be recommended? Eur J Nucl Med Mol Imaging 2007; 34:1704-1705.
23. 18F-FACBC may be a new promising marker for PET molecular imaging of prostate cancer. Radiotracer uptake was demonstrated in primary and metastatic disease.
24. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multifield-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297.
25. 18F FDG in bladder cancer imaging by PET/CT.
26. Picchio M, Treiber U, Beer AJ, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006; 47:938-944.
27. Gofrit ON, Mishani E, Orevi M, et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 2006; 176:940-944.
28. Kotzerke J, Linne C, Meinhardt M, et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging 2007; 34:884-888.
29. Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995; 36:1595-1601.
30. 124I-cG250 accurately identified clear-cell renal carcinoma; a negative scan was highly predictive of a less aggressive phenotype. Preoperative identification of tumour type in renal masses may have important implications for the choice of treatment and clinical management of the patients.
31. De Santis M, Pont J. The role of positron emission tomography in germ cell cancer. World J Urol 2004; 22:41-46.
32. 18FDG PET scanning is not sufficiently sensitive to identify patients at low risk of relapse.